Antiretroviral Drug Resistance Mutations in Antiretroviral‐Naive Prisoners

Stone, David R.; Corcoran, Colleen; Wurcel, Alysse G.; McGovern, Barbara; Quirk, James R.; Brewer, Arthur; Sutton, Lorraine; D’Aquila, Richard T.

doi:10.1086/342697

Cited by 11 publications

(14 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study reveals that RAMs exist in treatment-naive HIV-1 infected persons; similar findings have been reported by others [9][10][11][12][13][14]. The prevalence of RAMs in the present study (14.3%) is in agreement with studies done in Italy (12.5%) and the United States (16.0%) [9][10].…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Antiretroviral drug resistance and HIV-1 subtypes among treatment-naive prisoners in Kelantan, Malaysia

Ariffin

Mohamad

Yusuf

et al. 2014

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: The widespread use of highly active antiretroviral therapy (HAART) and continuous reports of HIV-1 strains developing resistance to these drugs is rather alarming, as transmission of resistant viruses to newly infected persons is possible. This study aimed to determine HIV-1 subtypes and the prevalence of primary mutations associated with antiretroviral (ARV) resistance among treatment-naive prisoners on the east coast of Malaysia. Methodology: Viral RNA was extracted from plasma samples of 21 treatment-naive prisoners. Protease (PR) and reverse transcriptase (RT) regions were amplified and sequenced. Stanford HIV database algorithms were used for interpretation of resistance, and phylogenetic analysis was performed for subtype assignment. Results: In the PR gene, no antiviral resistance-associated mutation was detected. For RT-associated mutations, K103N was the most prevalent in sequenced samples (14.3%). Genetic subtyping on the pol gene revealed that the majority of the prisoners were infected with subtype CRF33_01B (52.4%). Conclusion: Continuous surveillance of newly infected individuals is required to help strategize the best antiviral treatment for these patients.

show abstract

Section: Discussionsupporting

confidence: 92%

“…The prevalence of RAMs in the present study (14.3%) is in agreement with studies done in Italy (12.5%) and the United States (16.0%) [9][10]. However, in this study, the drug resistance assessment was limited to the pol region since entry and integrase inhibitors are not widely used in HIV patients in Malaysia.…”

Section: Discussionsupporting

confidence: 90%

Antiretroviral drug resistance and HIV-1 subtypes among treatment-naive prisoners in Kelantan, Malaysia

Ariffin

Mohamad

Yusuf

et al. 2014

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…1,2 However, the widespread use of ARV increased the prevalence of HIV drug-resistance, which may affect the efficacy of HAART for prevention of MTCT (PMTCT). [3][4][5][6][7][8][9][10][11] Furthermore, ARV resistance can also arise in mothers who receive HAART for PMTCT [12][13][14][15][16][17] and compromise future ARV responses in women [18][19][20][21] and/or complicate the management of HIV infection in infants born to mothers who failed PMTCT. [22][23][24][25] The guidelines for management of HIV infection in pregnancy in resource-abundant countries recommend resistance testing in all patients.…”

Section: Introductionmentioning

confidence: 99%

Resistance to antiretrovirals in HIV-infected pregnant women

Weinberg

Forster-Harwood

McFarland

et al. 2009

Journal of Clinical Virology

View full text Add to dashboard Cite

“…[7][8][9][10][11][12] Although the development of drug-resistant virus has important implications for treatment of HIV infection, little is known about the overall prevalence of ARV resistance among incarcerated persons, a population that carries a disproportionate burden of HIV. To date, there have been only five studies examining ARV resistance among prisoners-two in the United States 13,14 and three in Europe. [15][16][17] Of the two studies conducted in the United States, 13 one focused on 67 seroconverters during incarceration and restricted surveillance to only four major mutations.…”

Section: Introductionmentioning

confidence: 99%

“…14 The second study surveyed only 25 ARV treatment-naive prisoners. 13 The generalizability of the two studies conducted in the United States 13 is limited by their small sample sizes and by their focus on HIV-infected ARV treatment-naive prisoners.…”

Section: Introductionmentioning

confidence: 99%

Low Prevalence of Antiretroviral Resistance Among HIV Type 1-Positive Prisoners in the Southeast United States

Menezes

Rosen

Wohl

et al. 2013

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Drug-resistant HIV complicates management of HIV infection. Although an estimated 14% of all HIV-positive persons pass through a prison or jail in the United States each year, little is known about the overall prevalence of antiretroviral (ARV) resistance in incarcerated persons. All genotypic sequence data on HIV-positive prisoners in the North Carolina (NC) Department of Corrections (DOC) were obtained from LabCorp. Screening for major resistance mutations in protease (PI) and reverse transcriptase (NRTI and NNRTI) was done using Genosure and the Stanford HIV Database. For subjects with multiple genotype reports, each mutation was counted only once and considered present on all subsequent genotypes. Between October 2006 and February 2010, the NC DOC incarcerated 1,911 HIV(+) individuals of whom 19.2% (n=367) had at least one genotype performed. The overall prevalence of a major resistance mutation was 28.3% (95% CI 23.7, 33.0). Among prisoners ever exposed to an ARV during incarceration (n=329) prevalence of a major resistance mutation was 29.8% (95% CI 24.9, 34.7); resistance by class was 20.4% (95% CI 16.0, 24.7) for NRTIs, 19.8% (95% CI 15.5, 24.1) for NNRTIs, and 8.8% (95% CI 5.8,11.9) for PIs. Single class drug resistance was most prevalent at 14.2% (10.2,17.7) followed by dual 12.5% (I8.9,16.0) and triple class 3.3% (1.4,5.3) resistance. The three most prevalent mutations were K103N 15.8% (12.0, 20.2), M184V 14.3% (10.7,18.5), and M41L 4.9% (2.8,7.8). In the NC DOC ARV resistance prevalence, dual and triple class drug resistance was moderate over the study period. Resistance to PIs was lower than NNRTIs and NRTIs, likely reflecting higher usage of these two classes or a lower barrier to resistance.

show abstract

Antiretroviral Drug Resistance Mutations in Antiretroviral‐Naive Prisoners

Cited by 11 publications

References 10 publications

Antiretroviral drug resistance and HIV-1 subtypes among treatment-naive prisoners in Kelantan, Malaysia

Antiretroviral drug resistance and HIV-1 subtypes among treatment-naive prisoners in Kelantan, Malaysia

Resistance to antiretrovirals in HIV-infected pregnant women

Low Prevalence of Antiretroviral Resistance Among HIV Type 1-Positive Prisoners in the Southeast United States

Contact Info

Product

Resources

About